Posted: 4 August 2025
The National Reconstruction Fund Corporation (NRFC) has committed $150 million to Brandon Capital’s Brandon BioCatalyst 6 (BB6) fund, furthering efforts to develop and commercialise Australian-made therapeutics, medical devices, and vaccines.
The recenly announced funding was aimed at supporting both early and late-stage medical science ventures, enabling business creation, technical and clinical development, and job growth. With this contribution, the NRFC surpassed its $550 million investment target for the 2025 financial year.
“Our partnership with Brandon Capital will help to ensure that more of Australia’s world-class medical innovation makes the full onshore journey from laboratory to commercial viability so that highly skilled jobs can contribute to Australia’s commercialisation of important medical innovation.” said NRFC CEO David Gall. “If we want medical science jobs and industries to exist in Australia in ten years, we need to invest in them today.”
The investment was designed to strengthen Australia’s sovereign medical manufacturing capability, building long-term resilience in the nation’s medical science ecosystem, while helping to crowd-in future private capital.
Dr Chris Nave, Founding Partner and Managing Director of Brandon Capital, noted that “The NRFC’s investment is a vote of confidence in the future of Australian medical science, providing the opportunity for more of our local innovations to be developed into life-saving medical products, as well as creating jobs and income for the country.”
The collaboration marked a significant milestone in building long-term resilience across Australia’s health technologies ecosystem.
For more information click here.
